Xconomy National

Archives

by in

Entry	Author	Date	Location
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles	Luke Timmerman	12/23/11	Seattle
Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To Acquire	Luke Timmerman	11/04/11	San Francisco
Ambrx Grabs $24M Upfront in New Diabetes, Heart Failure Research Deal With Bristol-Myers	Luke Timmerman	09/22/11	San Diego
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies	Luke Timmerman	08/29/11	Seattle
Anaphore Snags $110M Deal With Mitsubishi Tanabe to Make Drugs for Immune Disorders	Luke Timmerman	12/13/10	San Diego
Sutro Biopharma Grabs $36.5M in Venture Deal to Make “Biobetters”	Luke Timmerman	11/17/10	San Francisco
Novartis-backed Genomics Institute Names Martin Seidel as New Director, Replacing Peter Schultz	Luke Timmerman	10/05/10	San Diego
How Novartis Got Its Vaccines Groove Back, Intellikine Gets a Drug Development Deal, Ambrx CEO Departs, & More San Diego Life Sciences News	Bruce V. Bigelow	07/15/10	San Diego
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline	Luke Timmerman	07/14/10	Seattle
Peter Schultz Exits Top Job at Genomics Institute of the Novartis Research Foundation	Luke Timmerman	07/14/10	San Diego
Ambrx CEO Steve Kaldor Departs	Luke Timmerman	07/12/10	San Diego
The 20-Year Outlook for San Diego Life Sciences: Sold Out? Not Anymore	Luke Timmerman	03/15/10	San Diego
The 20-Year Future of San Diego Biotech, Coming March 31	Luke Timmerman	03/09/10	San Diego
What Will San Diego’s Biotech Hub Look Like in 20 Years? Xconomy Event Takes Long View	Luke Timmerman	02/16/10	San Diego
Biogen Idec CEO Stepping Down, Ambrx Focuses on Empowered Antibodies, Intellikine Testing First Drug Candidate, & More San Diego Life Sciences News	Bruce V. Bigelow	01/07/10	San Diego
Ambrx, Saying Thanks to its Rivals, Rides Wave of Interest in “Empowered” Antibodies	Luke Timmerman	01/06/10	San Diego
Swine Flu Could Benefit Some Biomedical Companies, Local Biotechs Are Looking Healthier, Arena Happy With Obesity Drug Results, & More San Diego Life Sciences News	Bruce V. Bigelow	09/24/09	San Diego
Ambrx Strikes Deal With Wyeth (Soon-to-be Pfizer) to Make Antibody Drugs	Luke Timmerman	09/18/09	San Diego
Intellikine, Stocked With Cash, Pushes Portfolio of Drugs Against Biology’s Hot Targets	Luke Timmerman	08/18/09	San Diego
Wireless Medicine Gets $45M Booster Shot, Arena’s Weight-Loss Trial Underwhelms Wall Street, Venter’s Synthetic Genomics About to Ramp Up, & Other San Diego BizTech News	Bruce V. Bigelow	04/06/09	San Diego
Ambrx Gets $10 Million in Venture Round	Juha-Pekka Tikka	04/01/09	San Diego
Biogen Idec, Extending Life of its Top-Selling Drug, Eyes Longer-Lasting Shot for MS	Luke Timmerman	03/27/09	Boston
Biotech CEOs Discuss the Virtues of Going Virtual	Bruce V. Bigelow	03/26/09	San Diego
Pacira and Histogen Disclose Layoffs, Optimer Advances Diarrhea Drug, Torrey Path Comes to Town, & More SD BizTech	Bruce V. Bigelow	03/02/09	San Diego
UW’s Gardasil Windfall, Cell Therapeutics Unloads Zevalin, Trubion Cuts Jobs, & More Seattle-Area Life Sciences News	Luke Timmerman	02/26/09	Seattle
Ambrx Nails Down Partnership with Merck KGaA to Develop Multiple Sclerosis Drug	Luke Timmerman	02/24/09	San Diego
Ambrx Aims to Create New Breed of Custom-Built Biotech Drugs	Luke Timmerman	12/08/08	San Diego
Ambrx Garners $28,364,000 New Round	VentureDeal	06/30/06	San Diego
Page 1 of 1